![Microbiota intestinal: perspectivas futuras [podcast]](https://cellerafarma.com.br/wp-content/uploads/2021/09/microbiota-intestinal-perspectivas-futuras-podcast.jpg)
Neste episódio, produzido pela PEBMED em parceria com a Cellera Farma, Jôbert Neves, pediatra e especialista em Gastroenterologia Pediátrica recebe Vera Lucia Angelo, gastroenterologista e especialista em doenças funcionais e manometria para abordarem o que é microbiota intestinal e as perspectivas futuras do uso do probiótico. Confira!
Nós usamos cookies e outras tecnologias semelhantes para melhorar sua experiência em nossos serviços, personalizar publicidade e recomendar conteúdo de seu interesse.Ao utilizar nossos serviços você concorda com tal monitoramento.Confira nossa Privacy Policy.
ProsseguirNegarWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
"Cellera began its activities in May 2017 with the acquisition of Delta Farmacêutica and part of the assets of Valeant (now Baush Lomb), through the investment of Principia Capital Partners in partnership with Omilton Visconde Jr, a prominent entrepreneur in the Brazilian pharmaceutical market.
Since then, Cellera has built its path based on a unique and innovative business model, with a strategic focus on promoting and distributing established brands in the market. This operational model has provided us with accelerated growth and expanded our presence in the sector through major partnerships and acquisitions.
Thus, in the second year of operations, we acquired Pamelor (Novartis) and Benerva (Bayer), in addition to announcing, in the same year, the licensing of the world’s best-selling probiotic: Culturelle from I-health, a company of the DSM group. At that point, we materialized our entry into the prescription drug market.
The following year, we finalized a promotion and distribution agreement with Janssen Pharmaceuticals, which further strengthened our operation and allowed Cellera to double its size. Subsequently, new opportunities arose with the purchase of Tylex (Janssen), as well as new promotion and distribution agreements with Sanofi, Ferring, and Servier.
In fact, the Brazilian pharmaceutical market has some peculiarities. Large pharmaceutical companies generally focus their investments on innovation, directing resources towards the development of high-cost molecules, consequently reducing the promotion of important and prominent products.
Cellera identified an opportunity to take advantage of the 'long tail' of some medications, aiming to maximize the lifespan of these drugs, which often end up suffering a reduction in their promotion. In general, they are still very interesting products, with good revenue and significant sales opportunities. Some pharmaceutical companies, aligned with their investment strategies, prefer to seek partnerships to carry out the promotion and distribution of these drugs rather than discontinuing them. Our goal is precisely to ensure that these brands continue to gain market share."
Relatório de Equidade Salarial
Cartilha de Diversidade e Inclusão
Descarte de Medicamentos
Acesso restrito a profissionais de saúde. Faça seu login ou cadastre-se para ter acesso a conteúdos exclusivos.
[wpmem_form login]
